leflunomide has been researched along with Dermatoses in 9 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "The perforating dermatoses are a group of disorders characterized by transepidermal elimination of a material from the upper dermis." | 2.58 | Perforating disorder secondary to leflunomide and review of the literature of medications associated with perforating disorder. ( Keeley, JM; Pavlidakey, P; Sami, N, 2018) |
| "Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis." | 2.48 | Leflunomide in dermatology. ( Boyd, AS, 2012) |
| "When leflunomide was administered both at the time of primary and subsequent immunizations, reductions in total and specific serum IgE levels of > 80% and > 38%, respectively, were observed (P < 0." | 1.30 | Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. ( Bartlett, RR; Jarman, ER; Kuba, A; Montermann, E; Reske-Kunz, AB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keeley, JM | 1 |
| Pavlidakey, P | 1 |
| Sami, N | 1 |
| Bohelay, G | 1 |
| Bouaziz, JD | 1 |
| Nunes, H | 1 |
| Rybojad, M | 1 |
| Bagot, M | 1 |
| Petit, A | 1 |
| Laroche, L | 1 |
| Sehgal, VN | 1 |
| Verma, P | 1 |
| Boyd, AS | 1 |
| Frieling, U | 1 |
| Luger, TA | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
| Kurtz, ES | 1 |
| Bailey, SC | 1 |
| Arshad, F | 1 |
| Lee, AA | 1 |
| Przekop, PA | 1 |
| Jarman, ER | 1 |
| Kuba, A | 1 |
| Montermann, E | 1 |
| Bartlett, RR | 1 |
| Reske-Kunz, AB | 1 |
| Wozel, G | 1 |
| Pfeiffer, C | 1 |
6 reviews available for leflunomide and Dermatoses
| Article | Year |
|---|---|
Perforating disorder secondary to leflunomide and review of the literature of medications associated with perforating disorder.
Topics: Adult; Drug Eruptions; Elastin; Epidermis; Female; Humans; Immunosuppressive Agents; Leflunomide; Sk | 2018 |
Leflunomide: dermatologic perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Dermatologic Agents; Dihydroorotate D | 2013 |
Leflunomide in dermatology.
Topics: Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis; Skin Diseases | 2012 |
Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.
Topics: Administration, Oral; Autoimmune Diseases; Female; Fertility; Fetal Death; Humans; Immunosuppressive | 2002 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
[Leflunomide--a new drug for pharmacological immunomodulation].
Topics: Animals; Autoimmune Diseases; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis; | 2002 |
3 other studies available for leflunomide and Dermatoses
| Article | Year |
|---|---|
Striking leflunomide efficacy against refractory cutaneous sarcoidosis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; | 2014 |
Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bromodeoxyuridine; Cell Division; Chronic Disease; | 1995 |
Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Allergens; Animals; Antibody Formation; Down-Regulation; | 1999 |